Livedoid Vasculitis
Conditions
Keywords
Livedoid Vasculitis, smoking, thrombophilia
Brief summary
A screening of patient histories at the clinics of Dermatology of the universities of Zurich, Basel and Bern is performed in order to identify patients with a history of Livedoid vasculopathy. Patients with a history of livedoid vasculopathy are asked to participate in the study. After reading the patient information and if the informed consent is signed patients are included in the study. Patients are questioned about their smoking history and blood is drawn in order to perform a screening for thrombophilia.
Detailed description
A screening of patient histories at the clinics of Dermatology of the universities of Zurich, Basel and Bern is performed in order to identify patients with a history of Livedoid vasculopathy. Patients with a history of livedoid vasculopathy are asked to participate in the study. The presence of Livedoid vasculopathy must be confirmed by a histologic specimen. After reading the patient information and if the informed consent is signed patients are included in the study. Patients are questioned about their smoking history and blood is drawn in order to perform a screening for thrombophilia. The presence of a history of smoking and thrombophilia is compared to the general Swiss population.
Interventions
No intervention. Blood is drawn for analysis.
Sponsors
University of Zurich
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
10 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* History of livedoid vasculopathy
Exclusion criteria
* Diagnosis was not proved by biopsy specimen * A different reason than livedoid vasculopathy has been found for the symptoms of the patient * No informed consent by the patient
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Smoking history: Patients will be asked if they currently smoke or if they are former smokers. If one of both items is yes, it means a positive answer. | 22 months | The primary endpoint is the comparison of a positive smoking history and other cardiovascular risk factors of patients with livedoid vasculopathy with the Swiss general population. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Thrombophilia screening: the following parameters will be determined in every participant: Factor V Leiden, Prothrombin 20210; Protein C, Protein S, Antithrombin III, Beta 2 Glykoprotein 1, Lupus Antikoagulans | 22 months | The secondary endpoint is the search for thrombophilia in patients with livedoid vasculopathy. |
Countries
Switzerland
Outcome results
None listed